Pasithea Therapeutics Corp. — Investor Relations & Filings
Filings indexed
301
across all filing types
Latest filing
2026-05-15
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
KTTA
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. The company develops new therapeutics for neurological and psychiatric conditions, with a primary focus on Neurofibromatosis type 1 (NF1), a disorder causing tumor growth along nerves, and Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease. Its research also targets Multiple Sclerosis (MS), a chronic autoimmune disease of the CNS, and schizophrenia, a disabling psychiatric illness. The company's pipeline additionally includes treatments for solid tumors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| QUARTERLY REPORT | 2026-05-15 | English | |
| 8-K - PASITHEA THERAPEUTICS CORP. (0001841330) (Filer) | 2026-02-20 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G Filing | 2026-02-12 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 46363349 | QUARTERLY REPORT | 2026-05-15 | English | ||
| 32899636 | 8-K - PASITHEA THERAPEUTICS CORP. (0001841330) (Filer) | 2026-02-20 | English | ||
| 32021647 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32021493 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 32021479 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32021505 | SCHEDULE 13G Filing | 2026-02-12 | English | ||
| 32021490 | S-8 Filing | 2026-01-30 | English | ||
| 32021563 | 8-K Filing | 2026-01-28 | English | ||
| 13367478 | POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 | 2026-01-26 | English | ||
|
2025
6 filings
| |||||
| 13367481 | DEFINITIVE PROXY STATEMENT | 2025-12-29 | English | ||
| 13367482 | PRELIMINARY PROXY STATEMENT | 2025-12-19 | English | ||
| 13367480 | CURRENT REPORT | 2025-12-15 | English | ||
| 13367483 | Major Shareholding Notification 2025 | 2025-12-05 | English | ||
| 13367484 | Major Shareholding Notification 2025 | 2025-12-05 | English | ||
| 13367489 | CURRENT REPORT | 2025-12-02 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Annovis Bio, Inc.
A clinical-stage drug platform company developing therapies…
|
ANVS | US | Professional, scientific and te… |
|
AnorMED Inc.
Developed small molecule therapeutics for serious diseases,…
|
— | CA | Professional, scientific and te… |
|
ANTEOTECH LTD
Develops nanoglue technology for life sciences and lithium-…
|
ADO | AU | Professional, scientific and te… |
|
Anthem Biosciences Limited
Integrated CRAMS organization for drug discovery, developme…
|
ANTHEM | IN | Professional, scientific and te… |
|
APPLIED DNA SCIENCES INC
Develops and manufactures DNA-based technologies for geneti…
|
APDN | US | Professional, scientific and te… |
|
Aprea Therapeutics, Inc.
Clinical-stage biopharma developing cancer therapeutics via…
|
APRE | US | Professional, scientific and te… |
|
AprilBio Co.,Ltd.
Develops long-acting biologic drugs for autoimmune diseases…
|
397030 | KR | Professional, scientific and te… |
|
Aptahem AB
A clinical-stage biotech developing aptamer-based drugs for…
|
APTA | SE | Professional, scientific and te… |
|
APTAMER GROUP PLC
Develops custom affinity binders for research, diagnostics,…
|
APTA | GB | Professional, scientific and te… |
|
Aptevo Therapeutics Inc.
Clinical-stage biotech developing antibody-based immunother…
|
APVO | US | Professional, scientific and te… |
Pasithea Therapeutics Corp. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35389/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35389 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35389 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35389 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35389}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Pasithea Therapeutics Corp. (id: 35389)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.